Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) reduce the risk of colorectal cancer by 40-60% in animal carcinogen models, [1] [2] [3] human observational studies, 4 and familial adenomatous polyposis cohort studies. 5 NSAIDs exert their therapeutic antiinflammatory and antipyretic actions by inhibition of the enzyme cyclooxygenase and subsequent production of prostaglandins. 6 7 Two isoforms of cyclooxygenase have recently been identified: cyclooxygenase 1 (COX-1) is largely responsible for the constitutive production of prostaglandins and cyclooxygenase-2 (COX-2) is induced by proinflammatory stimuli. 8 9 Based on the ability of NSAIDs to inhibit colorectal cancer, it is tempting to infer a role for cyclooxygenase and prostaglandins in the genesis of this disease. Prostaglandins have well established roles in tumour promotion and angiogenesis, 10 and both prostaglandins (particularly PGE 2 ) and COX-2 mRNA are overexpressed in human and rodent colorectal tumours. [11] [12] [13] [14] Immunohistochemical studies of colorectal tumours from both animal and human studies suggest that COX-2 protein is found in neoplastic epithelial cells 11 15 as well as in colonic interstitial tissue, 14 particularly interstitial macrophages. 16 17 In addition, COX-2 protein is detected in vascular endothelial cells, fibroblasts, and cancer cells. 11 COX-1 protein may also be detected immunohistochemically in neoplastic epithelial cells, inflammatory mononuclear cells, vascular endothelial cells, and fibroblasts. 11 COX-2, rather than COX-1, appears to be the isoform that NSAIDs are targeting in colorectal cancer, as only one study (in carcinogen induced rodent colon tumours) has shown COX-1 to be upregulated. 18 Selective COX-2 inhibitors could prove potentially ideal agents for the prevention of colorectal cancer, given that they selectively target the relevant isoform of cyclooxygenase and have less toxicity than standard NSAIDs. aberrant crypt foci (ACF) [20] [21] [22] and colorectal tumours. 23 24 When doses of selective COX-2 inhibitors based on the therapeutic antiinflammatory dose were used, only a modest 20-25% reduction in the number of ACF was seen. [20] [21] [22] When the dose of the test agent was increased 10-fold, a more impressive 40% reduction in the total number of ACF was noted. 20 22 Only these supranormal doses have been tested in tumour models, 23 24 and while these doses are eVective in animals, doses of this magnitude are unlikely to be practical for potential clinical applications.
Although selective COX-2 inhibitors carry fewer gastrointestinal side eVects than standard NSAIDs, 19 they do have side eVects, particularly aVecting the renal tract 25 and the female reproductive system. 26 Toxicity is more likely when the dose is increased. Chemopreventive agents ideally have no toxicity. Therefore, it would be preferable if normal therapeutic antiinflammatory doses of selective COX-2 inhibitors could be used.
We have previously compared the eVect on the development of carcinogen induced ACF in animals treated with equivalent antiinflammatory doses of predominantly COX-1 inhibitors (indomethacin and sulindac), a selective COX-2 inhibitor (meloxicam), and a highly specific COX-2 inhibitor (celecoxib), and found equivalent inhibition in all treatment groups. 27 The fact that the chemoprotective power of NSAIDs is not reliant on the cyclooxygenase inhibitory profile suggests that the eVect of NSAIDs in colorectal cancer is not solely modulation of COX-2 and the cyclooxygenase-prostaglandin pathway.
This theory is supported by the eYcacy of non-cyclooxygenase active agents such as sulindac sulphone. 2 28 Further supportive evidence comes from studies which demonstrate that while sulindac eVectively inhibits tumorigenesis, tumour prostaglandin levels are unchanged. 29 30 One suggested mechanism for the action of these drugs is induction of apoptosis and regulation of cell proliferation. 31 We have designed a study comparing NSAIDs with varying activity against the two cyclooxygenase isoforms at equivalent, clinically relevant, anti-inflammatory doses in a rodent carcinogen induced colorectal tumour model. We have compared their eVects on tumour number and load, and quantified the eVect on tumour apoptosis and proliferation.
Methods

TEST AGENTS
The agents chosen, dose used, and relative activity against diVerent cyclooxygenase isoforms are shown in table 1. All drugs were pure substances.
COX-1 inhibitors used were indomethacin (Sigma Chemical Co, St Louis, Missouri, USA) and sulindac (Merck Sharp and Dohme, Sydney, Australia). Meloxicam (Boehringer Ingelheim, Sydney, Australia) is a selective COX-2 inhibitor. Celecoxib (Searle, St Louis, Missouri, USA) is a highly specific COX-2 inhibitor. Sulindac sulphone (Merck Sharp and Dohme) has no known anti-cyclooxygenase activity.
The doses of sulindac, sulindac sulphone, and indomethacin were based on previous work done by our group.
1-3 The normal adult human dose for indomethacin is 1-3 mg/kg/day and for sulindac 6 mg/kg/day (company information). The eVective chemopreventive dose for indomethacin was therefore in the normal therapeutic range and calculations for COX-2 inhibitors were based around equivalency for this drug.
Sulindac may be considered a standard chemopreventive agent which has been well studied in both human and animal experiments. The dose we found to be eVective was similar to that of other groups. 23 Therefore, the drug was included at its eVective dose, even though it was outside the normal clinical range, to allow for comparison at a so-called "eVective chemopreventive" dose.
The dose of meloxicam was calculated to be an equivalent anti-inflammatory dose to indomethacin on the basis of granuloma pouch studies (personal correspondence, Boehringer Ingelheim).
The dose of celecoxib was based on the published anti-inflammatory dose (Searle Monsanto, Chicago, Illinois, USA). The mean (SEM) serum level achieved with this dose of celecoxib at the end of the treatment period was 0.67 (0.07) µg/ml (assay kindly performed by Searle Monsanto). The reported minimum serum level required for maximal antiinflammatory eVect (therapeutic level) in rats is 0.3 µg/ml. 22 
TUMOUR MODEL
Induction of colonic tumours
Primary colonic tumours were induced with 1,2 dimethylhydrazine (DMH), as described previously. 29 DMH (Fluka Chemical Company, Castle Hill, NSW, Australia) is dissolved in isotonic saline and the pH adjusted to 7.0 with concentrated NaOH. Each animal received five weekly oral doses of DMH at 30 mg/kg per dose.
Treatment groups
Rats were randomised to a control group (n=12) or to treatment with test agents (table  1) . Drugs were administered in food; control animals received food containing vehicle alone. The amount eaten was monitored, and the mixture adjusted to ensure delivery of the required daily dose. Treatment commenced on the day after the first dose of DMH and 50 values vary according to the cell system used, the ratio stays relatively constant, as does ranking. 17 22 51-55 b Two animals from this group died after randomisation, one while being anaesthetised for blood collection, and the other had a large gastroduodenal tumour eroding his liver and hepatic vessels. continued for 23 weeks. A group of animals (n=10) not treated with DMH and who received the same food as control animals was also included. No tumours developed in these animals, and they will not be discussed further.
Tumour identification and measurement
One hour prior to colon removal, animals were injected intraperitoneally with the thymidine analogue bromodeoxyuridine (Brd-U) (SigmaAldrich, St Louis, Missouri, USA) at a dose of 200 mg/kg. They were anaesthetised with intraperitoneal pentobarbitone sodium 60 mg/kg (Boehringer Ingleheim, Sydney, Australia) and the colon removed via a midline laparotomy. The colons were opened along the mesenteric border, washed with isotonic saline, and pinned flat. The position, number, and volume of each tumour was recorded. The colons were fixed in 10% neutral buVered formalin (Sigma Scientific Co., St Louis, Missouri, USA) for 16-20 hours. Tumour tissue was processed, and embedded in paraYn. Sections of tissue (3 µm) were stained with haematoxylin and eosin for histological confirmation. Histological analysis was performed by two observers. Both observers were blinded to the treatment group.
Assessment of the rate of apoptosis within tumours
The rate of apoptosis in haematoxylin and eosin stained tumour tissue was measured using a modification of the technique described by Samaha and colleagues. 32 A sample of tumours from each group was studied with the observer blinded to the treatment group. Both the number of apoptotic cells and total number of tumour cells were counted in five random high power light microscopy fields (×1000 magnification under oil emersion) (Olympus CK2). The percentage of cells with apoptotic features was then calculated. The criteria used to recognise apoptotic cells were: shrunken size, loss of contact with surrounding tissue (at times forming the classically described halo), and nuclear condensation (fig 1) . 31 33 This was the only phase of apoptosis that we were able to consistently recognise. Apoptotic bodies were not counted, as in this model it was diYcult to distinguish them confidently from intraepithelial lymphocytes or debris resulting from formalin fixation.
Assessment of the rate of proliferation within the tumour tissue
The rate of proliferation within tumour tissue was determined using an immunohistochemical stain for Brd-U. A sample of tumours from each group was studied with the observer blinded to the treatment group. Sections of paraYn embedded tissue (3 µm) were deparaYnised and taken to water through serial alcohols and washed in phosphate buVered saline (PBS) (pH 7. 
Results
TUMOUR NUMBER
The mean number of tumours developing in control animals over the 23 Multiple comparison testing showed that sulindac sulphone was significantly less eVective than celecoxib (p=0.03) and indomethacin (p=0.004).
When the number of tumours was considered by histological type, we found that 37.3% of tumours in control animals were adenomas and 62.7% adenocarcinomas. This was significantly altered in animals treated with indomethacin and celecoxib, as no adenomas were found in these groups. In the other treatment groups the ratio of adenomas to adenocarcinomas was not significantly altered. In the sulindac group, 21.1% were adenomas and 78.9% adenocarcinomas. In the meloxicam group, 40.0% were adenomas and 60.0% adenocarcinomas. In the sulindac sulphone group, 42.3% were adenomas and 57.7% adenocarcinomas.
TUMOUR VOLUME The mean volume of tumour (tumour load) developing per animal in the control group was 1119.5 (459.7) mm 3 . This was significantly reduced in all treatment groups regardless of their cyclooxygenase inhibitory profile (fig 3) . In the group treated with predominantly COX-1 inhibitors, indomethacin treated animals developed a mean of 59. 3 , a reduction of 71% (p=0.029). Multiple comparisons between groups showed no one drug to be statistically more eVective than another.
RATE OF APOPTOSIS PER TUMOUR
Mean percentage of apoptotic cells recognised by our criteria was 1.16 (0.10)% in tumours from control animals: 42 of the total 51 tumours in this group were examined.
The rate of apoptosis was significantly increased in tumours of animals treated with all test agents. Of the tumours developing in animals treated with predominantly COX-1 inhibitors, indomethacin treated animals (five of a total of seven tumours studied) had 3.14 (0.55)% apoptotic cells, a 2.7-fold increase (p<0.001), and those treated with sulindac (13 of a total of 19 studied) had 4.26 (0.47)% apoptotic cells, a 3.7-fold increase (p<0.001). In tumours developing in animals treated with predominantly COX-2 inhibitors, meloxicam treated animals (16 of a total of 20 tumours studied) had 3.03 (0.32)% apoptotic cells, a 2.6-fold increase (p<0.001), and those treated with celecoxib (eight of a total of nine tumours studied) had 2.57 (0.32)% apoptotic cells, a 2.2-fold increase (p<0.001). In tumours developing in animals treated with sulindac sulphone (23 of a total of 26 tumours studied), there were 2.29 (0.19)% apoptotic cells, a 2.0-fold increase (p<0.001).
The relative rates of apoptosis between adenomas and adenocarcinomas are shown in fig 4. 
RATE OF PROLIFERATION PER TUMOUR
In tumours developing in control animals (11 tumours studied) there was a mean of 32.2 (3.2)% of cells in the S phase, as calculated 
Discussion
In this model of colon cancer, therapeutic antiinflammatory doses of COX-2 inhibitors were as eVective as a therapeutic dose of indomethacin, an eVective chemopreventive dose of sulindac (three times the normal antiinflammatory dose), and the noncyclooxygenase active drug sulindac sulphone. Clinically, this has important implications as COX-2 selective drugs at standard antiinflammatory doses are better tolerated than standard NSAIDs, 19 making them potentially better chemopreventive agents. This is the first study to examine celecoxib and meloxicam at therapeutic antiinflammatory doses in a carcinogen induced rodent tumour model. In the previous study of celecoxib at supranormal doses, there was a more profound eVect on mean tumour number with 98% reduction compared with 73% reduction in our study. However, the degree of inhibition of tumour volume was similar with 87% reduction when supranormal doses of celecoxib were used and 90% reduction in our study. 23 In ACF studies, therapeutic antiinflammatory doses of celecoxib either have no eVect 22 or a modest eVect (22% reduction) (Brown, paper submitted). With supranormal doses however a 41% reduction in the number of ACF was noted. 22 Therefore, it is possible that therapeutic anti-inflammatory doses of highly selective COX-2 inhibitors are exerting their inhibitory eVect later in the stepwise pathway of colorectal carcinogenesis (adenomas and carcinomas) whereas supranormal doses are having an eVect at an earlier stage.
No adenomas developed in animals treated with either indomethacin or celecoxib. In this model a subtype of colorectal tumour has been described which does not seem to have a preceding polyp phase. 34 It is possible that NSAIDs are preventing tumours arising from the classic polyp-carcinoma sequence but are only able to inhibit tumours from this alternate pathway. This would explain the absence of adenomas and reduced number and volume of adenocarcinomas. Further studies are underway to test this hypothesis further.
From the point of view of understanding the mechanisms underlying colorectal carcinogenesis, these data add further weight to the contention that NSAIDs are functioning in a novel fashion, and that regulation of apoptosis and cell proliferation is a key end point.
In normal tissue, cell replication must be matched by cell death to maintain tissue homeostasis. The process of tumorigenesis in the colon is characterised by a stepwise increase in resistance to apoptosis followed by an increase in proliferation. 35 36 These data indicate that the eVectiveness of NSAIDs against colorectal cancer can be explained, at least in part, by restoration of this critical balance between the rates of apoptosis and proliferation.
It has previously been demonstrated in this model 29 and in the min/+ mouse 30 that sulindac inhibits colorectal tumour development without reducing tumour prostaglandin levels. This suggests therefore that induction of tumour cell apoptosis and reduction in proliferation is not dependent on inhibition of prostaglandin production. However, it is possible that cyclooxygenase inhibition may have other sequelae.
Regulation of the cyclin D/cdk4&6 checkpoint seems to be a critical step in colorectal carcinogenesis as it controls the length of time a cell spends in G1. 37 Inhibition of cyclooxygenase causes build up of arachidonic acid which in turn is converted to syringomyelin and finally ceramide. 38 Ceramide has been shown to not only regulate the cyclin D/cdk4&6 checkpoint by dephosphorylation of Rb 39 but also to separately induce apoptosis by a bcl-2 dependent mechanism. 40 Inhibition of cyclooxygenase may also lead to positive feedback to the upstream regulators of cyclooxygenase transcription. Transcription of other related genes such as c-myc, bcl-2, and bax 41 could also be aVected. However, several lines of evidence suggest that the ability of NSAIDs to inhibit colorectal tumorigenesis is not dependant on cyclooxygenase inhibition. Drugs such as sulindac sulphone, 5-ASA, and olsalazine 42 also inhibit colorectal tumorigenesis by inducing tumour cell apoptosis and reducing tumour cell proliferation, yet these drugs do not inhibit cyclooxygenase. Furthermore, cell culture studies have shown that induction of apoptosis is independent of COX-2 protein expression. 43 44 Confirming this finding in vivo, we have recently found that increased expression of COX-2 in DMH induced rodent colorectal tumours is not altered by treatment with NSAIDs (unpublished data). The sum of these data suggests that NSAIDs are inhibiting colorectal cancer by a novel non-cyclooxygenase dependant mechanism.
The cyclin D/cdk4&6 checkpoint is inhibited by wild-type APC, 45 hDLG, 46 transforming growth factor , 47 COX-2, 48 and cdk inhibitors, including p21 WAF1 and p16 INK4 which are also under the control of p53. 45 In carcinogen induced rodent models of colorectal cancer, 15% of tumours have mutated APC protein 49 and 75% activating -catenin mutations. 50 Therefore, NSAIDs could be regulating this key checkpoint, either directly or through an eVect on biological inhibitors, reducing the number of proliferating cells, increasing the time in G1, and allowing apoptosis to occur.
This study is the first to directly compare the eYcacy of standard NSAIDs, a noncyclooxygenase active agent, and COX-2 inhibitors in a whole animal tumour model of colorectal cancer, at clinically relevant doses. It is also the first to demonstrate an increased rate of apoptosis and a reduced rate of proliferation in tumours treated with these agents. These data should be useful in planning clinical assessment of these agents for chemoprevention of colorectal cancer while also improving our understanding of underlying mechanisms.
